Penn's Division of Hematology/Oncology in the Department of Medicine provides comprehensive hematology and medical oncology research. The division, with its colleagues in other medical specialties, is an integral part of Penn's Abramson Cancer Center, an NCI-designated cancer center.
Specialized resources and research program include:
- Basser Center for BRCA
- Cancer Risk Evaluation Program
- Bone Marrow Failure Program and Myeloproliferative Disorders
Research at the Penn Blood Disorders Center
The Penn Blood Disorders Center conducts cutting-edge clinical research in non-malignant blood disorders including, but not limited to:
- Autoimmune hemolytic anemia
- Hemophilia
- Heparin-induced thrombocytopenia
- Immune thrombocytopenia (ITP)
- Sickle cell disease
- Thalassemia
- Thrombotic thrombocytopenic purpura (TTP)
- Venous thromboembolism
- Von Willebrand disease
At any one time, there are approximately 30 research studies open for enrollment. These include observational studies as well as clinical trials of new drugs and treatments. Some recent highlights of our research program include participation in gene therapy studies for hemophilia and in a clinical trial that led to FDA approval of a new treatment for thalassemia. Our patients have the opportunity to participate in this innovative research. In 2019 alone, 482 of our patients enrolled in research studies.
Hematology and oncology clinical trials
Penn's Abramson Cancer Center, an NCI-designated comprehensive cancer center, oversees one of the largest clinical trial programs in the country, with more than 200 trials available at any one time.